Clinical trials: Magnetic Resonance Angiography
Peripheral Arterial Disease
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
This study is an intra-individual comparison of DOTAREM®-enhanced MRA and GADOVIST®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.
- Trial name
- NCT00955617
- Testing
- Contrast-enhanced MRA - Imaging examination
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Guerbet
Diagnostic Imaging
Magnevist Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral…
- Trial name
- NCT01376739
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- Japan
- Volunteers
- 2,051 people
- Sponsor
- Bayer
Peripheral Arterial Disease (PAD)
Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
The purpose of this study is to compare the difference between two magnetic resonance imaging (MRI) techniques for visualizing arteries.
- Trial name
- NCT00707876
- Testing
- ferumoxytol
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Peripheral Vascular Disease
Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the infrarenal aorta and peripheral arteries.
- Trial name
- NCT00185276
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Volunteers
- 365 people
- Sponsor
- Bayer
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
- Trial name
- NCT00144547
- Testing
- MRA(Tocilizumab)
- Volunteers
- 241 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Study of MRA in Patients With Rheumatoid Arthritis (RA)
This is an open-label, extension, Phase II study to evaluate the long-term safety and efficacy of MRA in Patients with RA who were participated in Study MRA009JP.
- Trial name
- NCT00144651
- Testing
- MRA(Tocilizumab)
- Volunteers
- 135 people
- Sponsor
- Chugai Pharmaceutical
Arterial Occlusive Disease
A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography
This is a clinical study of gadoteric acid in non-coronary MR angiography.
- Trial name
- NCT00447889
- Testing
- gadoteric acid
- Where
- South Korea
- Sponsor
- Guerbet
Rheumatoid Arthritis
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT00721123
- Testing
- Tocilizumab
- Where
- 69 sites in Argentina, Australia and 15 more
- Volunteers
- 538 people
- Sponsor
- Hoffmann-La Roche
Peripheral Vascular Disease
Crossover Study With MultiHance vs a Comparator for Peripheral MRA
This is a double blind crossover study designed to compare two different gadolinium products given at the same dose to patients undergoing MRA assessment of lower legs for the evaluation of peripheral steno-occlusive disease.
- Trial name
- NCT00408083
- Testing
- MultiHance, Magnevist
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Bracco Diagnostics, Inc
Carotid, Aortic, Renal or Peripheral Artery Disease
Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
To compare two gadolinium contrast agents in terms of global paired diagnostic preference (primary endpoint) for the assessment of contrast-enhanced MR Angiography of the carotid, renal/abdominal and peripheral arteries
- Trial name
- VALUE (NCT01260636)
- Testing
- Gadobenate Dimeglumine, Gadopentetate Dimeglumine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bracco Diagnostics, Inc
Magnetic Resonance Imaging
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents.
- Trial name
- NCT00468819
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 14 sites in Austria, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Rheumatoid Arthritis
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.
- Trial name
- NCT00144560
- Testing
- MRA(Tocilizumab)
- Volunteers
- 31 people
- Sponsor
- Chugai Pharmaceutical
Steno-occlusive Disease
Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent
This is an explorative small pilot study comparing two MRA contrast agents, one of which has been on the market for a few years and the other fairly new to the market.
- Trial name
- NCT00415805
- Testing
- Multihance, vasovist
- Where
- Italy
- Volunteers
- 39 people
- Sponsor
- Bracco Diagnostics, Inc
Rheumatoid Arthritis
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
A 52-week follow up study to investigate the duration of maintenance of efficacy in patients with RA and achieved low disease activity in clinical trials of MRA and stopped the treatment
- Trial name
- NCT00661284
- Where
- 5 sites in Japan
- Volunteers
- 189 people
- Sponsor
- Chugai Pharmaceutical
Systemic Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
- Trial name
- NCT00144612
- Testing
- MRA(Tocilizumab)
- Volunteers
- 60 people
- Sponsor
- Chugai Pharmaceutical
Systemic Juvenile Idiopathic Arthritis
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
This is a double-blind, Phase III study to evaluate the efficacy, safety and PK of MRA in patients with sJIA.
- Trial name
- NCT00144599
- Testing
- MRA(Tocilizumab)
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.
- Trial name
- NCT00144586
- Testing
- MRA(Tocilizumab)
- Volunteers
- 42 people
- Sponsor
- Chugai Pharmaceutical
Steno-occlusive Disease
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI
- Trial name
- NCT07348640
- Testing
- gadopiclenol, Gadoterate meglumine (Dotarem)
- Where
- 43 sites in United States, Canada and 8 more
- Volunteers
- 315 people
- Sponsor
- Guerbet
Renal Artery Obstruction
Gadobutrol Enhanced MRA of the Renal Arteries
Subjects referred for a routine CTA (computed tomography angiography) or MRA (magnetic resonance angiography) will be invited to participate in the study and subjects will be involved in the study for between 2 and 12 days.
- Trial name
- GRAMS (NCT01344460)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in United States, Argentina and 11 more
- Volunteers
- 317 people
- Sponsor
- Bayer
Stenosis
Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Stenosis in the Calf and/or Pedal Arteries
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Magnevist (the study drug) used for MRI of the calf and foot arteries.
- Trial name
- NCT00309075
- Testing
- Gadopentetate dimeglumine (Magnevist)
- Volunteers
- 126 people
- Sponsor
- Bayer